Evotec AG has entered into a research collaboration with Immuneering Corp., a data-driven drug discovery provider, to discover novel small molecules for rare hereditary metabolic diseases. Financial details were not disclosed. Evotec will leverage its induced pluripotent stem cell (iPSC) platform and drug discovery capabilities and Immuneering will apply its Artificial Intelligence drug discovery platform in an effort to accelerate ligand identification for novel targets. As part of the colla...